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Background: Methicillin-resistant Staphylococcus aureus (MRSA) is spreading worldwide and poses a serious public
health problem, being present in hospital settings and communities. However, from the Middle East and the
Arabian Peninsula few molecular typing data on MRSA strains are currently available. In order to obtain data on the
population structure of MRSA in Riyadh, Saudi Arabia, 107 clinical and environmental MRSA isolates were
genotyped using a microarray-based assay.
Results: Five major MRSA strains from four clonal complexes were identified CC8/ST239-III (20.75%), PVL-positive as
well as -negative CC22-IV (18.87% and 9.43%, respectively), PVL-positive CC30-IV (12.26%) and PVL-positive CC80-IV
(17.92%). Minor strains, which accounted for less than 3% each, included CC1-IV/SCCfus, PVL-positive CC1/ST772-V,
PVL-positive as well as- negative CC5-IV, CC5-IV/SCCfus, CC5-V, CC6-IV, CC45-IV, PVL-negative CC80-IV, PVL-positive
CC88-IV, CC97-V and a CC9/ST834-MRSA strain.
Conclusions: Typing of MRSA strains from Riyadh revealed a high diversity of clonal complexes. The prevalence of
the genes encoding the Panton-Valentine leukocidin was surprisingly high (54.21%), and a significant rate of
resistance markers was detected also in strains considered as community-associated.
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Methicillin-resistant Staphylococcus aureus (MRSA)
infections remain a major healthcare burden considering
the emergence of more virulent community-acquired
or -associated MRSA (CA-MRSA) in addition to the
longer existent hospital-acquired (HA-) MRSA strains.
While an abundance of MRSA typing data from the
United States, Western Europe and Australia are avail-
able, comparable data for the Middle East are generally
scarce. With regard to HA-MRSA strains, the pandemic
strain ST239-III appears to be widespread in the region
[1-5]. That strain was reportedly common in Saudi* Correspondence: monecke@rocketmail.com
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reproduction in any medium, provided the orArabia during the 1990s [6]. Another pandemic strain,
CC22-IV (UK-EMRSA-15) has been detected in Kuwait
[7] and Abu Dhabi [2]. Studies in various hospitals and
several countries indicated an increased number of
CA-MRSA infections confirmed by strain typing data.
PVL-positive strains, which are usually regarded as
community-associated, have been found in Kuwait [8],
Abu Dhabi [2], Lebanon [9], Egypt [10], Tunisia [11],
Algeria [12,13] as well as in people travelling from and
to various Middle Eastern countries [14].
In Riyadh, the capital of the Kingdom of Saudi Arabia,
an increasing number of MRSA cases has been detected
since the application of an infection control policy re-
quiring a systematic MRSA screening of patients prior
to admission in hospitals in 2008 [15,16]. The MRSA
prevalence in patients seen in King Fahad Medical City
in Riyadh was 50.4% for the year 2011 (unpublished in-
ternal statistics, based on susceptibility tests of isolatesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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order of magnitude to other hospitals in Saudi Arabia
[17]. According to an earlier one year study (2005) per-
formed in a hospital in the Western region of Saudi Ara-
bia [18], the MRSA prevalence was 38.9% of which
78.8% showed resistance to erythromycin, gentamicin
and oxytetracycline. The prevalence of CA-MRSA in a
hospital in the Eastern region increased by six-fold dur-
ing a 5-year period, between 2000 and 2008 [19].
To obtain the first MRSA typing data concerning
Saudi Arabian patients, one hundred and seven MRSA
isolates from King Fahad Medical City (KFMC) in Riy-
adh were characterised using DNA microarrays.
Results
Altogether, 102 patient isolates were analysed for this
study. Detailed data on patients' demographics and the
origin of samples are provided as Additional file 1.
For ten isolates, clinical and patient data could not be
retrieved; for two additional isolates, patient data were
not available. Out of the ninety isolates for which demo-
graphic data were available, 57 (63.33%) originated from
male patients and 33 (36.67%) from females. The mean
age of patients was 26, the median 22 years. Patients car-
rying ST239-III were older than average (mean, 43 years;
median, 39 years).
Additionally, five isolates from four environmental
samples collected by the Infection Control & Environ-
mental Health Department (IC & EH) were included.
This included two PVL-negative CC22-IV, two PVL-
positive CC22-IV and one PVL-positive CC30-IV.
Prevalence of resistance- and virulence-associated genes
Table 1 shows which percentages of clinically important
genes, i.e., resistance or virulence associated markers,
SCCmec elements and agr groups were found among
the studied isolates.
Most significantly, the prevalence of the genes encod-
ing the Panton-Valentine leukocidin (lukF/S-PV) was
high (54.21%).
Clonal complexes and strains
Isolates were assigned to CCs and strains based on hy-
bridisation profiles as defined previously [20,21]. Five
major MRSA clones from four clonal complexes (CC)
predominated. These highly prevalent strains included
CC8/ST239-III, (Vienna/Hungary/Brazil Epidemic Strain),
PVL-positive CC22-IV and PVL-negative CC22-IV
(UK-EMRSA-15/Barnim Epidemic Strain), PVL-positive
ST30-IV (Southwest Pacific Clone) and PVL-positive
CC80-IV (European CA-MRSA Clone). Sporadic MRSA
strains included PVL-negative CC5-IV, CC5-IV/SCCfus,
CC6-IV (West Australian, WA, MRSA-51/66) and PVL-
positive CC88-IV, PVL-positive CC5-IV, PVL-negativeCC80-IV, CC97-V as well as CC1-IV/SCCfus (WA
MRSA-1/45), PVL-positive CC1/ST772-V (Bengal Bay
Clone/WA MRSA-60), PVL-negative CC5-V, CC45-IV
(WA MRSA-23) and a CC9/ST834-MRSA strain with an
unidentified SCCmec element.
Some major international MRSA clones, such as
CC5-II (New-York-Japan Clone, USA100, UK-EMRSA-3
or Rhine-Hesse Epidemic Strain), PVL-positive ST8-IV
(USA300), CC30-II (UK-EMRSA-16 or USA200), or
CC45-II (USA600) were not detected among the tested
sample population.Strain descriptions
Short strain profiles with regard to the carriage of
resistance- or virulence-associated genes and to other
genes of relevance for the determination of CCs are
shown in Table 2. Full hybridisation profiles are provided
in the Additional file 1.Clonal complex 1
Two isolates were identified that belong to CC1. One
PVL-negative isolate carried SCCmec IV as well as ccrA-
1, ccrB-1 and the fusidic acid resistance marker
Q6GD50 (fusC, GenBank BX571857.1:SAS0043). Thus it
can be regarded as identical to the West Australian
(WA) strain WA MRSA-45 and some of the isolates ori-
ginally described as WA MRSA-1 [20,23].
The other isolate was identified as PVL-positive
ST772-V, also known as Bengal Bay Clone or WA
MRSA-60. This is a distinct clone which differs from
other CC1 strains in several features such as in the agr
allele (II rather than III), capsule type (5 rather than 8),
carriage of the enterotoxin-like gene ORF CM14 (Gen-
Bank U10927.2) and the absence of the enterotoxin H
gene seh.Clonal complex 5
Both, PVL-negative as well as PVL-positive CC5-IV
(Paediatric Clone or USA800) as well as one PVL-
negative CC5-V isolate were found.
Three isolates belonged to a strain previously known
only from Malta [22]. It is characterised by the presence
of the fusidic acid resistance marker Q6GD50 (fusC) and
additional recombinase genes beside a SCCmec IV
element [22]. One out of these isolates harboured, beside
egc, also tst1, sec and sel (encoding toxic shock syn-
drome toxin, enterotoxins C and L).Clonal complex 6
Three isolates belonged to CC6-IV, which is identical to
the Australian strains WA MRSA-51 and −66. They
lacked PVL, but carried sea.













mecA 107 100.00 lukF-PV+ lukS-PV 58 54.21
SCCmec I, SCCmec II 0 0.00 tst1 8 7.48
SCCmec III 22 20.56 sea 9 8.41
SCCmec IV 76 71.03 sea-N315 5 4.67
SCCmec IV/SCCfus (CC1) 1 0.93 seb 2 1.87
SCCmec IV/SCCfus (CC5) 3 2.80 sec + sel 3 2.80
SCCmec V 4 3.74 sed 2 1.87
atypical SCCmec (ST834) 1 0.93 see 0 0.00
merA +merB 14 13.08 egc 54 50.47
blaZ 100 93.46 seh 1 0.93
erm(A) 21 19.63 sej + ser 3 2.80
erm(C) 30 28.04 sek + seq 24 22.43
msr(A) 9 8.41 ORF CM14 1 0.93
mph(C) 7 6.54 etA, etB, edinC 0 0.00
aacA-aphD 37 34.58 etD 21 19.63
aadD 8 7.48 edinA 1 0.93
aphA3+ sat 38 35.51 edinB 21 19.63
dfrA 28 26.17 ACME 0 0.00
far1 17 15.89 sak 103 96.26
Q6GD50 (fusC) 7 6.54 chp 70 65.42
tet(K) 11 10.28 scn 104 97.20
tet(M) 22 20.56 agr group I 58 54.21
cat 1 0.93 agr group II 10 9.35
qacA 20 18.69 agr group III 38 35.51
mupA, ermB, cfr, fexA, vanA 0 0.00 agr group IV 1 0.93
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All 22 CC8 isolates belonged to ST239-III, which is a di-
vergent strain that emerged from an incorporation of a
large fragment of CC30 DNA [24,25]. All these isolates
harboured the beta-lactamase-operon and tet(M) (tetra-
cycline resistance) as well as, variably, further resistance
genes as shown in Table 2. All isolates carried entero-
toxin genes sek and seq.
Patients carrying this strain were older than average
(mean, 43 years; median, 39 years).Clonal complex 9/sequence type 834
ST834 is a distinct sequence type within CC9 that dif-
fers in several markers including the alleles of the regu-
latory locus agr (agr group I rather than II) and of
some adhesion factors (bbp, map, vwb), in capsule type
(8 rather than 5) and spa type and in the presence of
sasG (encoding S. aureus surface protein G).One isolate was identified as CC9/ST834 being essen-
tially identical to the Australian strain ST834-IV, or
WA MRSA-13, in all markers but the SCCmec element.
It yielded signals for mecA, a truncated signal trans-
ducer protein mecR1, ugpQ (a glycerophosphoryl diester
phosphodiesterase gene, associated with mecA), ccrB-4
and Q6GD50 (fusC) as well as beta-lactamase and msr
(A) (macrolide resistance). This strain carried tst1, sec
and sel, but lacked PVL genes.Clonal complex 22
CC22 was common; and PVL-positive as well as PVL-
negative CC22-IV were identified.
Eighteen patient samples and two environmental sam-
ples were PVL-positive CC22-IV. All isolates harboured
the beta-lactamase-operon and aacA-aphD. Other
common resistance genes included aadD (tobramycin),
erm(C) and dfrA (trimethoprim resistance). Virulence
Table 2 Characterisation of MRSA strains detected within this study
CC Strain Number and
percentage of isolates
Resistance-associated genes Virulence-associated genes Other relevant markers
1 CC1-IV/SCCfus
(WA MRSA-1/45)
1 (0.93%) mecA (SCCmec IV), blaZ/I/R, ccrA/B-1, Q6GD50 (fusC) lukD/E, sea, seh, sek, seq, sak/scn, agr III, capsule type 8, cna, sasG
CC1/ST772-V [PVL+]
(Bengal Bay Clone)
1 (0.93%) mecA (SCCmec V), blaZ/I/R, msr(A),
mph(C) aacA-aphD, aphA3/sat
lukF/S-PV, sea, sec, sel, egc-cluster,
ORF CM14, scn
agr II, capsule type 5, cna, sasG
5 CC5-IV (Paediatric Clone) 3 (2.80%) mecA (SCCmec IV), blaZ/I/R, erm(C) (in 2/3) lukD/E, seb (in 1/3), egc-cluster,
edinA (in 1/3)
agr II, capsule type 5, sasG
CC5-IV [PVL+]
(Paediatric Clone)





agr II, capsule type 5, sasG
CC5-IV/SCCfus
("Maltese Clone", see [22])
3 (2.80%) mecA (SCCmec IV), ccrA-3,
Q6GD50 (fusC), blaZ/I/R (in 2/3)
lukD/E, tst1 (in 1/3), sea, sec/l (in 1/3),
egc-cluster, sak/scn
agr II, capsule type 5, sasG
CC5-V 1 (0.93%) mecA (SCCmec V), aacA-aphD lukD/E, sea-N315, sed/j/r,
egc-cluster, sak/scn
agr II, capsule type 5, sasG




22 (20.56%) mecA (SCCmec III), merA/B (in14/22), ccrC
(in 21/22), blaZ/I/R, erm(A)
(in 21/22), erm(C) (in 1/22), aacA-aphD (in 13/22),
aphA3/sat (in 13/22),
tet(M). tet(K) (in 3/22), cat (in 1/22), qacA (in 20/22)
lukD/E, sea (in 1/22), sek/q,
sak/scn, chp (in 1/22)
agr I, capsule type 8, cna, sasG
9 CC9/ST834-(atyp. SCCmec) 1 (0.93%) mecA, delta mecR, ugpQ, Q9XB68-dcs, ccrB-4, Q6GD50
(fusC), blaZ/I/R, msr(A)
lukD/E, tst1, sec/l, sak/chp/scn agr I, capsule type 8, sasG
22 CC22-IV (Barnim/UK-EMRSA-15) 10, including
2 environmental
samples (9.35%)
mecA (SCCmec IV), blaZ/I/R, erm(C)
(in 1/10), msr(A) (in 1/10),
aacA-aphD (in 1/10), tet(K) (in 1/10), dfrA
tst1 (in 6/10), egc-cluster,
sak/chp/scn (in 9/10)/
agr I, capsule type 5, cna, sasG
CC22-IV [PVL+] 20, including
2 environmental
samples (18.69%)
mecA (SCCmec IV), blaZ/I/R, erm(C) (in 17/20),
aacA-aphD, aadD
(in 8/20), dfrA (in 19/20)
lukF/S-PV, egc-cluster, sak/chp/scn agr I, capsule type 5, cna, sasG
30 CC30-IV [PVL+]
(USA1100, Southwest




mecA (SCCmec IV), blaZ/I/R (in 12/13), erm(C)
(in 1/13), msr(A)/mph(C)
(in 6/13), aphA3/sat (in 6/13)
lukF/S-PV, egc-cluster, sak/chp/scn agr III, capsule type 8, cna
45 CC45/agr IV-IV (WA MRSA-23) 1 (0.93%) mecA (SCCmec IV), blaZ/I/R sej/r, egc-cluster, sak/chp/scn agr IV, capsule type 8, cna, sasG
80 CC80-IV 2 (1.87%) mecA (SCCmec IV), blaZ/I/R, erm(C),
aphA3/sat (in 1/2), far1 (in 1/2)
lukD/E, seb/k/q (in 1/2), edinB, etD,
sak/scn, chp (in 1/2)
agr III, capsule type 8, sasG
CC80-IV [PVL+]
(European caMRSA Clone)
19 (17.76%) mecA (SCCmec IV), blaZ/I/R (in 16/19),
erm(C) (in 4/19), aphA3/sat
(in 16/19), far1 (in 17/19), tet(K) (in 2/19)
lukF/S-PV, lukD/E, edinB, etD, sak/chp/scn agr III, capsule type 8, sasG
88 CC88-IV [PVL+] 3 (2.80%) mecA (SCCmec IV), blaZ/I/R, tet(K) (in 2/3) lukF/S-PV, lukD/E, sea-N315 (in 2/3),
sak/chp/scn (in 2/3)
agr III, capsule type 8, sasG
97 CC97-V 2 (1.87%) mecA (SCCmec V), Q6GD50 (fusC), blaZ/I/R,
aacA-aphD (in 1/2), tet(K) (in 1/2)
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toxin genes were identified.
Eight patient samples and two environmental sam-
ples were PVL-negative CC22-IV, i.e. identical or simi-
lar to the UK-EMRSA-15/Barnim Epidemic Strain.
One of the environmental strains originated from the
same sample as one of the PVL-positive CC22-IV.
Since it was identical to it with regard to all markers
but PVL genes, being positive for erm(C), dfrA and
aacA-aphD, it is likely that it was in fact a deletion
variant of that strain. The tst1 gene was detected in
six isolates, but enterotoxin genes sec and sel were not
found.Clonal complex 30
Thirteen samples, including one environmental, belonged
to PVL-positive CC30-IV (USA1100, Southwest Pacific
or WSPP Clone). These isolates could be clustered into
three variants based on the carriage of resistance genes.
One variant (six isolates) harboured the beta-lactamase
gene, but lacked other resistance markers. A second
variant (one isolate) lacked blaZ, but carried erm(C).
The third variant (six isolates) was positive for beta-
lactamase, msr(A) and mph(C) as well as aphA3 and sat.
Virulence-associated genes included lukF/S-PVL and egc;
other enterotoxin genes were not found.Clonal complex 45
One single isolate of CC45-IV was found. It differed
from the CC45-IV or Berlin Epidemic Strain, which is
commonly detected in Western Europe, in harbouring
sasG as well as different alleles of the agr locus (agr IV
rather than I) and of adhesion factors fnbA, fnbB, sdrD
and vwb. Thus it was related or identical to the WA
MRSA-23 strain and to isolates previously identified in
Hong Kong [20]. The isolate carried beta-lactamase as
well as enterotoxin genes sej and ser.Clonal complex 80
Two different CC80-IV strains were observed, one being
PVL-positive and the other one PVL-negative. Two iso-
lates were PVL-negative CC80-IV; one of them har-
boured enterotoxin genes seb, sek and seq.
Nineteen isolates from eighteen patients belonged to
the PVL-positive CC80-IV strain (European CA-MRSA
or WA MRSA-17/30). Six different variants of that
strain could be differentiated based on various combina-
tions of resistance genes blaZ, erm(C), aphA3 + sat, far1
and tet(K). One patient carried two isolates which dif-
fered in carriage of blaZ and far1. All PVL-positive
CC80-IV isolates also harboured edinB and etD, but no
enterotoxin genes were found.Clonal complex 88
Three isolates belonged to a PVL-positive CC88-IV
strain. Two out of three were positive for the distinct
variant of the enterotoxin A gene, sea-N315 or sep,
which is mainly known from the CC5 genome sequence
of strain N315 (BA000018.3: SA1761).
Clonal complex 97
Two isolates were identified as CC97-V. Both harboured
the beta-lactamase operon and Q6GD50, one was posi-
tive for aacA-aphD and tet(K). Both isolates lacked PVL
as well as other exotoxin genes.
Discussion
A striking result of the study was a high diversity of dif-
ferent MRSA strains and clonal complexes as well as a
high prevalence of PVL. The most common strains iden-
tified during this study were ST239-III, PVL-positive
and -negative CC22-IV, PVL-positive CC30-IV and PVL-
positive CC80-IV.
ST239-III is a pandemic clone which is mainly
hospital-associated. This might be the reason why car-
riers of that strain were older than the average. ST239-
III was previously identified in various Middle Eastern
countries including Abu Dhabi [2], Iran [3], Iraq [1],
Saudi Arabia [4] and Turkey [5]. PVL-positive CC22-IV
has been previously found in Great Britain and Ireland,
Germany and Abu Dhabi [2]. Middle Eastern isolates,
i.e., those from Abu Dhabi [2] and from the present
study, generally differed from European ones in carrying
additional resistance markers (aacA-aphD, aadD, dfrA).
PVL-negative CC22-IV represents a pandemic strain
known as UK-EMRSA-15, or Barnim Epidemic Strain.
This strain is increasingly common in Western Europe
and has also been found in Malta [22], Kuwait [7] and
Abu Dhabi [2]. However, with an incidence of only 8.9%
among our isolates it was distinctly less common than
in Western Europe, where 50-95% of MRSA isolates
might belong to that strain [20,22,26-29]. Its prevalence
was also markedly low compared to a study from Abu
Dhabi [2], where this strain accounted for 27.4% of
MRSA isolates. This observation might be attributed to
different population structures, to different patient col-
lectives served by the respective hospitals and to a sig-
nificant presence of European expatriates in the United
Arab Emirates. Isolates of that strain from both, Riyadh
and Abu Dhabi, often harboured tst1, which is normally
absent from European isolates. Interestingly, the tst1
gene in that strain was not accompanied by sec and sel
genes. This might indicate another genetic background
than the previously characterised tst1-carrying patho-
genicity island SaPI1 [30]. PVL-positive CC22-IV have
been described from Bavaria, Germany [31] as well as
from Australia [20,32,33], England [34,35] and Ireland
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and in German patients with family ties to Turkey
[14] as well as the present study might suggest that
this strain is common and widespread in the Middle
East. PVL-positive CC30-IV is a strain mainly known
from the Pacific islands, Samoa and New Zealand, but
also from Abu Dhabi [2] and Kuwait [8]. An import-
ation of that strain into Gulf countries appears to be
likely due to the high numbers of immigrant labourers
from Pacific countries such as the Philippines, as simi-
larly noted in Denmark [36]. PVL-positive CC80-IV
has been dubbed the European CA-MRSA strain as it
is widespread although sporadically detected across
several European countries. However, it appears to be
more predominant in the Middle East and Maghreb
(North African) countries being detected not only in
Saudi Arabia but also in Abu Dhabi [2], Kuwait [37],
Lebanon [9], Tunisia [11] and Algeria [12].
Other strains were rare being identified only in spor-
adic cases, accounting for less than 3% each. Some of
the minor strains have been previously observed in other
regions so that an importation might be likely. For
others no, or only few, data on distribution or preva-
lence are available. Therefore it is not clear if they
emerged locally or if they have been imported. For in-
stance, CC1/ST772-V is known to mainly occur in India
and Bangladesh, and cases in Europe are usually linked
to these countries [35,38]. There might also be an epi-
demiological link to India for the isolate from this study,
as there are high numbers of Indian workers, including
healthcare workers, in Riyadh. CC5-IV is known to
occur essentially worldwide. CC5-IV/SCCfus has been
described only from Malta [22], so it would be interest-
ing to check whether this strain has a wider distribution
in the Mediterranean countries and the Middle East.
CC6-IV has previously been observed not only in Aus-
tralia, but also in Abu Dhabi [2]. Interestingly, CC6-
MSSA has been found to be a common clone in Middle
Eastern camels [39] so that a local emergence of CC6-IV
after inter-species transfer and acquisition of a SCCmec
element appears to be possible. PVL-negative CC80-IV
appear to be extremely scarce, and the few detected iso-
lates might be deletion variants of the so-called Euro-
pean CA-MRSA clone. One of the two isolates identified
in this study carried enterotoxin genes, which is also a
rare feature among CC80. PVL-positive CC88-IV are
known from Abu Dhabi and, sporadically, from Europe.
CC97-V has been previously identified in Egypt, which
warrants further study on its presence in the Middle
East. Since CC97 MSSA are common among domestic
animals, here again a possible transmission from live-
stock should be investigated.
The MRSA strains found in Saudi Arabian patients
showed a significantly high carriage of PVL genes(54.21%). Comparable high figures have been reported
from Algeria [13] as well as from Abu Dhabi (41.9%,
[2]). These are much higher proportions than observed
in Western European countries [20,32,33]. Reasons for
this difference are largely unknown. A possible explan-
ation was a generally higher carriage of PVL in S. aureus
from the Middle East, possibly related to climatic or host
factors. If that was the case, the frequency of PVL-
positive-methicillin susceptible S. aureus (MSSA) should
also be high. However, data on MSSA from this region
are currently not yet available. In order to understand
the local epidemiology of PVL, further studies need to
focus on MSSA as well as on MRSA in Middle Eastern
countries.
It also might be speculated that PVL-MRSA just
replaced PVL-MSSA in the Middle East, possibly
favoured by a liberal use of antimicrobial drugs during
the last decades. Interestingly, previously published
MRSA genotyping data from Saudi Arabia showed a
much lower PVL prevalence of only 8% (three out of 37)
in SCCmec IV strains isolated from skin tissue infections
from patients seen in outpatient clinics in Riyadh in
2007 [40]. This finding may possibly relate to the small
number of isolates processed or to a different patient
collective. It might also indicate a massive expansion of
PVL-positive MRSA clones during very recent years.
This is also in accordance to an otherwise observed in-
crease in CA-MRSA infections [19]. These observations
emphasise the need for a more systematic surveillance
of this potential public-health hazard.
Another interesting finding was that resistance markers
that are traditionally associated with HA-MRSA (e.g.,
aacA-aphD, aadD) were common among CA-MRSA
strains. For instance, all PVL-positive CC22-IV in this
study carried aacA-aphD. Thus, the detection of, e.g.,
gentamicin resistance in a clinical isolate must not be
used to rule out a community origin or a possible pres-
ence of PVL in that actual isolate; and the decision to
perform a molecular assay for PVL should be guided by
the clinical symptoms of the patient rather than by the
susceptibility profile of the isolate.
Conclusion
A number of very diverse MRSA strains were found in
Riyadh, Saudi Arabia in addition to a long established
healthcare-associated MRSA strain (ST239-III). The
prevalence of Panton-Valentine leukocidin genes was
surprisingly high (54.21%), with PVL-positive clones also
being present in a healthcare setting. A significant rate
of resistance markers was detected in strains usually
considered as community-associated. This is a rather dif-
ferent situation than in European countries. Screening
and eradication programs thus need to focus not only
on patients, but also on contact persons such as family
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are still needed to understand the epidemiology of
MRSA in Saudi Arabia, possible changes in population
structures during the last decades and possible sources
for importation of epidemic strains from other regions.
Methods
Specimen collection and bacterial strains
The KFMC is a 1,400-bed tertiary care centre managing
mainly Saudi Arabian paediatric and adult patients. In
compliance with KFMC IC & EH policy, each patient is
screened for MRSA prior to hospital admission by PCR
using the BD GenOhm MRSA assay according to manu-
facturer's instructions (Becton Dickinson, USA). Patients
were isolated in wards according to MRSA PCR results
and all PCR-positive samples were cultured.
Isolates for the study were collected between summer
2010 and spring 2011. Sample types for the respective
isolates are listed in the Additional file 1.
Five isolates related to environmental swabbing of
areas near patients which were considered as potential
sources of infection. Seven isolates (six from nasal swabs
and one from sputum, see the Additional file 1) origi-
nated from screening samples. Another six isolates came
from nasal and oral swabs taken during diagnostic pro-
cedures. The remaining isolates included 50 from swabs
from skin lesions, abscesses etc., 15 from blood cultures,
nine from respiratory samples, two from urines, two
from drains and one from cerebrospinal fluid. For ten
isolates, data could not be retrieved.
Isolates were subjected to antimicrobial microbial
susceptibility testing (Becton Dickinson Phoenix, USA,
according to Clinical & Laboratory Standards Institute
guidelines) and submitted for array-based MRSA typing
to the Faculty of Medicine, Dresden, Germany. Approval
from the KFMC Institutional Review Board was obtained
to use patient isolates for this study. Individual patient´s
consent was not sought as isolates were derived from
routine diagnostics and as data were processed anonym-
ously. Copy strains, i.e., multiple isolates from one indi-
vidual patient were excluded from further analysis unless
they differed in array hybridisation profiles. This was the
case for four individual patients.
Array procedures
For characterisation of isolates, the StaphyType DNA
microarray (Alere Technologies GmbH, Jena, Germany)
was used. This DNA microarray covers ca. 170 genes
and their allelic variants. This includes species markers,
typing markers (SCCmec, capsule and agr group), resist-
ance genes as well as genes encoding exotoxins and ad-
hesion factors. A list of the included target genes as well
as primer and probe sequences have been published pre-
viously [20,21].Procedures were performed according to protocols as
recommended by the manufacturer and as previously
published [20,21]. In short, MRSA were cultured on
Columbia blood agar, harvested and enzymatically lysed
prior to DNA preparation using an automated system
(EZ1, Qiagen, Hilden, Germany). The purified DNA was
used as template in a linear primer elongation reaction
during which biotin-16-dUTP was incorporated into
the resulting amplicons. Reaction products were hybri-
dised to the microarray. After washing and blocking,
horseradish-peroxidase-streptavidin conjugate was added
which bound to the biotin labels. After further incuba-
tion and washing, a dye was added which locally precipi-
tated in presence of the peroxidase. This resulted in the
formation of visible spots on the array at these positions
where hybridisations occurred. An image of the micro-
array was taken and analysed using a designated reader
and software (Alere Technologies GmbH, Jena, Ger-
many). Analysis allowed to determine the presence or ab-
sence of the target genes as well as, by comparison to a
database of reference strains, the assignment to clonal
complexes as previously defined by MLST [41] and
eBURST analysis of MLST data (http://saureus.mlst.net/
eburst/). Sequence types which differ in nucleotide poly-
morphisms affecting MLST genes (such as ST22 and
ST1117) cannot be differentiated. However, STs which
originate from recombination events such as CC8/ST239
or CC30/ST34 [24,25] can be identified as well as some
other STs which differ from their respective parent
lineage such as CC1/ST772 or CC8/ST72. Epidemic
strains are defined and identified based on profiles and
MLST data previously described [20,21].
Additional file
Additional file 1: Patient demographics and full hybridisation
profiles.
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